EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

被引：1
|
作者：
Powles, Thomas
van der Heijden, Michiel Simon
Loriot, Yohann
Bedke, Jens
Valderrama, Begona P.
Iyer, Gopa
Kikuchi, Eiji
Hoffman-Censits, Jeannie
Vulsteke, Christof
Drakaki, Alexandra
Rausch, Steffen
Arafat, Waddah
Park, Se Hoon
Swami, Umang
Li, Jian-Ri
Gorla, Seema Rao
Homet Moreno, Blanca
Yu, Xuesong
Lu, Yi-Tsung
Gupta, Shilpa
机构：
[1] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, London, England
[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France
[4] Univ Paris Saclay, Dept Essais Precoces, Villejuif, France
[5] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany
[6] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany
[7] Hosp Univ Virgen del Rocio, Seville, Spain
[8] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, New York, NY USA
[9] St Marianna Univ, Dept Urol, Sch Med, Kawasaki, Kanagawa, Japan
[10] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[11] Maria Middelares Hosp, Dept Med Oncol, Antwerp, Belgium
[12] Univ Calif Los Angeles, Los Angeles, CA USA
[13] Eberhard Karls Univ Tubingen, Dept Urol, Tubingen, Germany
[14] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[15] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[16] Univ Utah, Dept Med, Huntsman Canc Inst, Salt Lake City, UT USA
[17] Taichung Vet Gen Hosp, Dept Surg, Div Urol, Taichung, Taiwan
[18] Astellas Pharma Inc, Northbrook, IL USA
[19] Merck & Co Inc, Rahway, NJ USA
[20] Pfizer Inc, Bothell, WA USA
[21] Cleveland Clin, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.664
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
    Van Der Heijden, Michiel Simon
    Powles, Thomas
    Gupta, Shilpa
    Bedke, Jens
    Kikuchi, Eiji
    De Wit, Ronald
    Galsky, Matt D.
    Duran, Ignacio
    Necchi, Andrea
    Retz, Margitta
    Yu, Evan Y.
    Hoffman-Censits, Jean H.
    Iyer, Gopa
    Park, Se Hoon
    Su, Wen-Pin
    Parmar, Hema
    Guan, Xuesong
    Gorla, Seema Rao
    Homet Moreno, Blanca
    Valderrama, Begona Perez
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : LBA530 - LBA530
  • [2] Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
    Kikuchi, E.
    van der Heijden, M. S.
    Perez Valderrama, B.
    Gupta, S.
    Bedke, J.
    Shin, S. J.
    Li, J-R.
    Guo, J.
    Danchaivijitr, P.
    Kanesvaran, R.
    Park, S. H.
    Su, W-P.
    Kandori, S.
    Bae, W. K.
    Wong, A. S.
    Lu, J.
    Yu, X.
    Shetty, A.
    Bavle, A. A.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1507 - S1508
  • [3] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Valderrama, B. Perez
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Gauna, D. E. Castellano
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    van der Heijden, B. M. S. Homet Moreno
    ANNALS OF ONCOLOGY, 2023, 34 : S1340 - S1340
  • [4] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Perez Valderrama, B.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano Gauna, D. E.
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1557 - S1558
  • [5] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
    Van Der Heijden, Michiel Simon
    Gupta, Shilpa
    Bedke, Jens
    Valderrama, Begona Perez
    Kikuchi, Eiji
    Iyer, Gopa
    Loriot, Yohann
    Dawson, Nancy Ann
    Hoffman-Censits, Jean H.
    Mar, Nataliya
    Sridhar, Srikala S.
    Maroto-Rey, Pablo
    Shin, Sang Joon
    Yu, Evan Y.
    Duran, Ignacio
    Birrenkott, Matthew
    Yu, Xuesong
    Shetty, Aditya
    Bavle, Abhishek Amar
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
    Bedke, Jens
    Van Der Heijden, Michiel Simon
    Powles, Thomas
    Valderrama, Begona Perez
    Kikuchi, Eiji
    Iyer, Gopa
    Vulsteke, Christof
    Swami, Umang
    Castellano, Daniel
    Sarwar, Naveed
    Drakaki, Alexandra
    Hoffman-Censits, Jean H.
    Arafat, Waddah
    Andabekov, Timur
    Li, Jian-Ri
    Lu, Yi-Tsung
    Yu, Xuesong
    Shetty, Aditya
    Moreno, Blanca Homet
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Powles, T. B.
    Van der Heijden, M. S.
    Gupta, S.
    Perez Valderrama, B.
    Galsky, M. D.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Rey, J. P. Maroto
    Vulsteke, C.
    Iyer, G.
    Swami, U.
    Shin, S. J.
    Rodriguez-Vida, A.
    Wozniak, M.
    Moreno, B. Homet
    Lu, J.
    Yu, C.
    Hogdal, L.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1137 - S1138
  • [8] Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
    van der Heijden, M. S.
    Gupta, S.
    Galsky, M. D.
    Derleth, C.
    Steinberg, J.
    Kataria, R.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S605 - S606
  • [9] The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin, David J.
    Kalebasty, Arash Rezazadeh
    Prasad, Vinay
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 313 - 315
  • [10] Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).
    Van der Heijden, Michiel Simon
    Gupta, Shilpa
    Galsky, Matt D.
    Derleth, Christina Louise
    Lee, Sue
    Kataria, Ritesh S.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345